ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...

Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership.

Biocytogen and Whitehawk ink global collaboration to develop bispecific antibody-drug conjugates: Boston Wednesday, July 8, 2026, 15:00 Hrs [IST] Biocytogen, a global biotechnolog ...

Novartis has agreed to acquire Myricx Bio, a London-based developer of next-generation antibody-drug conjugates (ADCs), for ...

Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) ...

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using ...

Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's ...

An updated edition of the May 18, 2026, article. The global oncology market is evolving rapidly, fueled by rising cancer incidence, an aging population and continued scientific innovation. According ...

CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate ...

Merck’s MRK stock is trading above its 50-day and 200-day simple moving averages (SMAs), a positive technical signal that ...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced the launch of ZetaOmics, the computational-biology module of its multi-agentic AI ...